Our global vision: Global medicine, Pharmaceutical quality.
Cann Pharma is market ready in Australia – with a drug portfolio of 16 existing medicinal grade cannabis products recommended by physicians and used by patients in Israel today for a myriad of medical diseases and conditions.
Cann Pharmaceutical Ltd of Israel has ten years of licensed experience in Israel and is one of few global 100% organic, chemical free producers of phytocannabinoid products.
We have a pathway for patients to secure access to our market ready and proprietary Cannabidiol (CBD) Enriched Epilepsy treatment EP1 from imports.
EP1 is our lead product for drug resistant epilepsy (DRE) in children, adolescents and adults.
Cann Pharma has a large number of proprietary strains that will be 100% organically cultivated and manufactured in Australia into proven phytocannabinoid pharmaceutical-grade drugs and treatments for specific medical conditions.
Other medical conditions we have medicinal cannabis treatments for include: Autism, Central Nervous System Pain, Palliative Care, PTSD and certain Cancers.
Our clinical study pipeline is designed to leverage the ten years of clinical experience of doctors and patients.